Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212380 · ClinicalTrials.gov registry record · Phase 1
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
A Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01212380 is a Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 21 participants, below the 60-participant average among 19 other Refractory Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01212380, a Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL), or prolymphocytic leukemia (PLL).
Conditions Studied
Interventions
- DRUG carfilzomib
- OTHER Cytokine Assessment
- OTHER Pharmacodynamic Studies
- OTHER Proteosome Inhibition Assessment
- OTHER Pharmacogenomic Studies
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212380
The ClinicalTrials.gov registry entry for NCT01212380 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 19 other Refractory Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Refractory Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which carfilzomib is the first listed.
NCT01212380 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01212380 about?
NCT01212380 is a clinical study titled "Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)". RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lym...
What is the current status of trial NCT01212380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-10. Estimated completion is 2015-09.
What conditions does trial NCT01212380 study?
This clinical trial studies the following conditions: Refractory Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Hematopoietic/Lymphoid Cancer.
What interventions are being tested in trial NCT01212380?
The interventions under investigation include: carfilzomib (DRUG), Cytokine Assessment (OTHER), Pharmacodynamic Studies (OTHER), Proteosome Inhibition Assessment (OTHER), Pharmacogenomic Studies (OTHER).
Who is sponsoring clinical trial NCT01212380?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01212380 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Chronic Lymphocytic Leukemia
All registered trials for this condition
Recurrent Small Lymphocytic Lymphoma
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.